| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5729724 | European Urology Focus | 2016 | 11 Pages |
Abstract
In this review we summarise evidence on the optimal sequence of anticancer drugs for metastatic castration-resistant prostate cancer. No agent has proven superior to another as front-line treatment, and the exact impact of prior treatments on drug efficacy is unknown. Better biomarkers for treatment selection and evaluation of response to treatment will be needed to personalise the optimal sequence for each individual patient.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono,